The the interest stems from industry investors recognize that KALY’s technology is undervalued.
DALLAS, Oct. 23, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company has recently received serious interest from an investor exploring the acquisition of KALY’s Cannabis Extract Biopharmaceutical Technology.
KALY CEO Frederick Ferri commented on the acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology indicating that the interest stems from industry investors recognizing that KALY’s technology is undervalued.
